This local, prospective, non-interventional, multi-center study includes patients treated with Riociguat for inoperable CTEPH(Chronic thromboembolic pulmonary hypertension)/ persistent or recurrent CTEPH after surgical treatment. It is planned to include a total of 400 patients (valid for safety analysis). This study is performed as an all-case investigation. The treatment of Riociguat is performed based on the product label in Japan. The standard observation period is 12 months from the 1st treatment of Riociguat. Safety and effectiveness are evaluated at 4th and 12th month. In addition, the extension observation is carried out once a year for 7 years at the longest to collect information on safety and effectiveness as long as Riociguat treatment continues. When the treatment of Riociguat is terminated, observation of a patient ends. For each patient, the investigator records data as defined in the protocol at each evaluation point by using the Electronic Data Capture (EDC) system. The duration of the study is approximately 9 years from launch.
Study Type
OBSERVATIONAL
Enrollment
1,298
The treatment of Riociguat should comply with the local product information (start dose: 3 mg/day, maximum dose: 7.5 mg/day)
Unnamed facility
Multiple Locations, Japan
Number of participants with treatment emergent adverse events and adverse drug reactions
Time frame: up to 8 years
Change from baseline in 6MWD (6-Minute Walking Distance) after 4 and 12 months
Time frame: baseline and 4 months, and 12 months
Change from baseline in Pulmonary Vascular Resistance (PVR) after 4 and 12 months
Time frame: baseline and 4 months, and 12 months
Change from baseline in TRPG (Tricuspid Regurgitation Pressure Gradient) after 4 and 12 months
Time frame: baseline and 4 months, and 12 months
Change from baseline in BNP/NT-pro BNP after 4 and 12 months
Time frame: baseline and 4 months, and 12 months
Change from baseline in WHO (World Health Organization) functional class after 4 and 12 months
Time frame: baseline and 4 months, and 12 months
Time to Clinical Worsening
The first occurrence of the following events is recorded and will be considered for the calculation of the combined endpoint: • Death (all-cause mortality) • Heart/lung transplantation • Rescue Pulmonary Endarterectomy, Rescue Balloon Pulmonary Angioplasty or Hospitalization due to persistent worsening of Pulmonary Hypertension • Start of new PH specific treatment due to worsening Pulmonary Hypertension. • Persistent decrease in 6MWD due to worsening pulmonary hypertension • Persistent worsening of functional class due to deterioration of Pulmonary Hypertension.
Time frame: up to 8 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.